e-Therapeutics (LSE:ETX) Growth Rank : 0 (As of Jun. 20, 2024)

View and export this data going back to 2007. Start your Free Trial

What is e-Therapeutics Growth Rank?

e-Therapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

e-Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of e-Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

e-Therapeutics (LSE:ETX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » e-Therapeutics PLC (LSE:ETX) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

ETXPF:USA

Address

4 Kingdom Street, Paddington, London, GBR, W2 6BD

Website

https://www.etherapeutics.co.uk

e-Therapeutics PLC is a drug discovery company. Its ambition is to transform the drug discovery process, leveraging its computational network biology platform (drug discovery) to find novel targets to address mechanisms underpinning complex disease. l company activities are carried out in the UK.

e-Therapeutics (LSE:ETX) Headlines

From GuruFocus

Eaton Vance Municipal Income 2028 Term Trust Announces Telephonic Annual Meeting Of Shareholders On November 12, 2021

By PRNewswire PRNewswire • 11-02-2021